Trial Profile
An Observational Research on Relationship Between c-Met Gene Polymorphism, Promoter Methylation Level, Related Drug Metabolism Enzymes and Crizotinib's Hepatic Toxicity in Non-small Cell Lung Cancer Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacogenomic
- 01 Mar 2021 Status changed to completed as per results published in the Journal of Cancer Research and Clinical Oncology.
- 01 Mar 2021 Results assessing relationship between genes related to RTK downstream signaling pathways and crizotinib-induced hepatic toxicity in ALK-positive non-small cell lung cancer patients published in the Journal of Cancer Research and Clinical Oncology.
- 17 Mar 2016 New trial record